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Abstract 
 
Assessing compounds for their pharmacological and toxicological properties is of 
great importance for industry and regulatory agencies. In this study an approach 
using open source software and open access databases to build screening tools 
for receptor-mediated effects is presented. The retinoic acid receptor (RAR), as a 
pharmacologically and toxicologically relevant target, was chosen for study. RAR 
agonists are used in the treatment of a number of dermal conditions and specific 
types of cancer, such as acute promyelocytic leukemia. However, when 
administered chronically, there is strong evidence that RAR agonists cause 
hepatosteatosis and liver injury. After compiling information on ligand-protein-
interactions, common substructures and physico-chemical properties of ligands 
were identified manually and coded into SMARTS strings. Based on these 
SMARTS strings and calculated physico-chemical features, a rule-based 
screening workflow was built within the KNIME platform. The workflow was 
evaluated on two datasets: one with RAR agonists exclusively and another large, 
chemically diverse dataset containing only a few RAR agonists. Possible 
modifications and applications of screening workflows, dependent on their 
purpose, are presented. 
 
1. Introduction 
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Predicting and understanding the properties of new chemical entities is not 
trivial, whether in the development of novel pharmaceuticals or in assessing 
potential toxicity. However, in silico, Quantitative Structure-Activity Relationship 
((Q)SAR) and read-across approaches provide a means of rapidly obtaining 
information (Blackburn and Stuard, 2014; Patlewicz et al., 2013; Cronin et al., 
2013). These can be supported by, or developed from, mechanistic 
understanding (Zhu et al., 2014). Additionally the concept of the Adverse 
Outcome Pathway (AOP), i.e. describing a sequence of causally linked events at 
different biological levels, is increasingly being applied to investigate adverse 
effects (Vinken et al., 2013). Models may be developed from knowledge of the 
first key event of an AOP, the molecular initiating event (MIE). In AOP 
terminology the MIE is followed by cellular and organ responses, which may 
ultimately result in an adverse effect to an organ, organism or population 
(Ankley et al., 2010). The MIE represents the initial interaction between 
molecule and the target. Examples of MIEs include covalent binding to DNA and, 
of relevance for this study, receptor binding (Gutsell and Russell, 2013; Allen et 
al., 2014). In pharmacology the mode of action, similar to an AOP, incorporates a 
MIE which describes how a compound interacts with specific proteins, e.g. 
receptors, carriers and enzymes. Instead of an adverse effect, the aim in 
pharmacology is, to achieve a beneficial effect, such as the prevention or 
treatment of a disease (OECD, 2012; FDA, 2013). 
 
Toxicity may also be brought about by interactions with specific proteins, such 
as receptors. Endocrine disruptors, for example, are a class of toxicants known to 
cause their effects by receptor-mediated mechanisms. As such, models for 
endocrine disruption are usually built around knowledge of receptor 
interactions, e.g. binding to the oestrogen receptor. For instance, one approach to 
modelling these effects has been proposed recently by Kolšek et al. (2014) who 
developed a tool to identify nuclear receptor ligands based on AutoDock Vina; a 
freeware to investigate ligand-protein-interactions (Molecular Graphics 
Laboratory, 2014). Limitations of this type of approach are associated with 
several of the typical issues of docking. First, nuclear receptors, particularly the 
 3 
non-steroid receptors, are considered to be flexible (Nettles et al., 2007). An 
inflexible docking model, such as AutoDock Vina, is unlikely to cope with the 
diversity of ligands (cf. full, partial, inverse agonists and antagonists). The second 
limitation, when docking is applied on its own, is that kinetics are systemically 
ignored, which might be vital for in vivo biological activity, such as target-organ-
toxicity (Campbell, 1983; Davis and Riley, 2004).  
 
The current study focuses on the retinoic acid receptor (RAR), a target relevant 
for pharmacology and toxicology in equal measure. The RAR is a nuclear 
receptor which can be divided into three subtypes, RAR-α, RAR-β and RAR-γ. 
Bound together with the retinoid X receptor (RXR) as a heterodimer, RAR 
regulates genetic expression. All three subtypes of the RAR are activated by all-
trans retinoic acid and 9-cis retinoic acid, which are derivatives of vitamin A (Liu 
et al., 2014). Ligands are used in the treatment of dermal diseases, e.g. Acne 
vulgaris, Psoriasis vulgaris, Keratosis pilaris and specific types of cancer, such as 
acute promyelocytic leukemia (Alizadeh et al., 2014; Leyden et al., 2005; Allen 
and Bloxham, 1989; Dicken, 1984). The toxicological effects of RAR agonists 
include changes in lipid metabolism, which may cause hepatosteatosis and 
leading to liver inflammation, fibrosis and eventually liver failure. Teratogenic 
effects and neural disorders, such as nausea and headache, have been also 
reported from retinoids (Moya et al. 2010; Adams, 1993; Biesalski, 1989; Shalita, 
1988). There is, therefore, a great need to develop tools to identify these 
compounds which show these effects. 
 
There are many open source software applications and open access databases 
supporting modern life sciences and informatics. A number of these open 
access/source technologies can be utilised to develop tools and approaches for 
predictive and/or computational toxicology. Some technologies relevant to this 
study are described below. 
 
The KoNstanz Information MinEr (KNIME) technology is freely available 
software to analyse and mine data, as well as to build and evaluate predictive 
models. The software is based on a graphical user interface utilising so called 
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“nodes” as key units to alter and process data in a “workflow”. The basic KNIME 
workflow technology, as well as many nodes and add-ons for chemo-informatics, 
is available from www.knime.org. Many types of data can be handled, including 
chemical formats, such as the Simplified Molecular Input Line Entry System 
(SMILES) and SMiles ARbitrary Target Specification (SMARTS) strings (Daylight, 
2014). KNIME has a strong community of developers building additional nodes 
for chemo-informatics applications (amongst others), to edit data, calculate 
physico-chemical properties, analyse structural features etc. It has been shown 
to be useful in developing workflows for screening tools (Saubern et al., 2011) in 
the context of predictive toxicology (KNIME, 2013). Furthermore, many other 
programming languages, such as R, Python or Perl, can be used within a KNIME 
workflow (KNIME, 2014; Richarz et al., 2013; Berthold et al., 2007).  
 
With regard to biological activity, there are an increasing number of resources 
available.  For instance, ChEMBL is a database of bioactive molecules comprising 
over 1.5 million compounds and over 9,000 biological targets. Activity values are 
reported for a variety of endpoints including Ki, Kd, AC50, IC50, and EC50. The 
database is curated manually and maintained by the European Molecular Biology 
Laboratory (ChEMBL, 2014). A good example of the application of ChEMBL and 
the utilisation of its resources was published by Czodrowski (2013). In that 
study, a detailed analysis of ChEMBL hERG assay data was used to build 
classification models relevant for drug development and demonstrated the 
applicability of these data for modelling and value that may result from data 
mining (Czodrowski, 2013). 
 
Another valuable resource is the Protein Data Bank (PDB) which contains over 
100,000 crystallographic structures of proteins such as receptors, transporters 
and enzymes. A quarter of these protein structures are of human origin, the 
other structures are from other mammals (mainly rodents) and bacteria. For 
some proteins, such as the RAR, there are data for several subtypes, species and 
ligands (PDB, 2014; Berman et al., 1999). Besides the linked publications for 
every entry, ligand-protein-interactions can be investigated with specific 
software, for example the freely available PyMOL (PyMOL, 2014). Visualisation 
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of protein structures of targets, such as receptors, transporters and enzymes, 
and their corresponding ligands helps to understand ligand-protein-interactions, 
e.g. hydrogen bonds between ligand and ligand-binding-domain of the protein. 
 
Whilst there is a growing number of computational resources, some of which 
have been developed for computational toxicology, up until now there has been 
little effort, and few publications demonstrating the utility of these disparate 
sources of information and techniques. The aim of this investigation, therefore, 
was to present a hands-on approach to develop screening tools applicable for 
many pharmacological and toxicological challenges. The methods applied are 
based firstly on gathering publically available data on RAR ligands (from 
ChEMBL and PDB) and secondly extracting information on physico-chemical 
space and structural features that are relevant to activity. Thirdly, this 
information was used to build a rule-based screening tool within KNIME. The 
purpose of the screening tool in this study was to identify potential RAR ligands. 
RAR is only one example target, i.e. this approach was designed to provide a 
framework that can, in principle, be used to create screening tools for other 
receptors should sufficient data be available. 
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2. Methods 
 
The RAR and its ligands were investigated solely using freeware (N.B. PyMOL is 
free for academic users only) and open access databases. 
 
2.1 Analysis of RAR ligands using the PDB 
 
The PDB 3.3 (PDB, 2014) was searched for human RAR structures, i.e. RAR-α, 
RAR-β and RAR-γ. The structures obtained were investigated visually with 
regard to their ligand-protein-interaction within PyMOL 1.3. Common structural 
features of the ligands, particularly when apparently responsible for similar 
ligand-protein-interactions, were extracted. The extracted structural features 
combined information about molecular distances and electric forces, which may 
be responsible for hydrogen bonding or the occupation of lipophilic pockets. 
Subsequently the structural features were coded manually into SMARTS strings. 
These SMARTS strings were later used in the rule-based workflow to predict 
potential RAR ligands.  
 
2.2 Extracting data from ChEMBL 
 
The ChEMBL_19 (ChEMBL, 2014) database was searched for the target “RAR”. 
Human data from compounds with Ki (binding affinity), Kd (dissociation 
constant), AC50 (50% activity in molar units) and EC50 (50% effect concentration 
in molar units) values towards RAR-α, RAR-β and RAR-γ were downloaded, 
combined and sorted by the pChEMBL value. The pChEMBL value is an approach 
to standardise different types of activity values (Bento et al., 2013). Every 
compound with a value of not less than five was regarded as being active. This is 
consistent with the activity interpretations of the ChEMBL database. 
 
2.3 Physico-chemical property calculation 
 
The physico-chemical properties of RAR ligands were calculated using the CDK 
node for molecular properties within KNIME 2.9.4 (incl. community 
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contributions). Ranges (i.e. minimum and maximum values) for different types of 
calculated descriptors for the active ligands were studied including: vertex 
adjacency information magnitude (VAIM) for structural complexity, number of 
rotational bonds (RB) for flexibility, molecular weight (MW) for molecular size 
and the logarithm of the water-octanol partition coefficient (XLogP) for 
lipophilicity. These four descriptors and their calculated property ranges were 
utilised to give an insight into the physico-chemical applicability domain (i.e. 
space) of active RAR ligands. 
 
2.4 Building rules for the screening workflow 
 
The analysis of the PDB has provided structural features coded as SMARTS 
strings; whilst the analysis of the ChEMBL dataset provided physico-chemical 
property ranges. Both describe the necessary features for compounds to be 
active RAR ligands. These features can be interpreted as rules, where compliance 
and violation will distinguish between RAR ligands and non-ligands respectively.  
These rules, characterising the physico-chemical space (CDK node for molecular 
properties) and structural features (Indigo substructure matcher), were written 
into a KNIME workflow. When executed, this KNIME “screening workflow” will 
identify potential RAR ligands.  
 
2.5 Testing the screening workflow 
 
The RAR ligands, identified from the ChEMBL dataset, were used to test if all 
active compounds were identified by the “screening workflow”. Since no external 
validation dataset was available, the dataset of hepatotoxicants provided by 
Fourches et al. (2010) was screened.  The Fourches dataset is a large, chemically 
diverse dataset (951 compounds), which contains hepatotoxic and non-
hepatotoxic drug molecules, including several RAR ligands (Fourches et al., 
2010). As the number of RAR ligands is unknown, the performance statistics 
(sensitivity, specificity etc.) of the screening workflow cannot be calculated, and 
the predictions for the Fourches dataset are for illustration only. This approach 
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cannot be considered a full validation as the Fourches data could include liver 
damage by a number of mechanism not restricted to RAR binding. 
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3. Results 
 
This study utilised a number of data sources, such as the PDB for ligand-protein-
interactions and the ChEMBL database for chemical structures of active 
compounds against RAR. 
 
3.1 Ligand-protein-interaction in RAR 
 
20 human RAR protein structures bound to different ligands were retrieved from 
the PDB. These were 4JYG, 4JYH, 4JYI, 4DQM, 4DM6, 4DM8, 3KMR, 3KMZ, 1XAP, 
1FD0, 1FCX, 1FCY, 1FCZ, 1DSZ, 1EXA, 1EXX, 3LBD, 4LBD, 2LBD and 1HRA (PDB, 
2014). Independent of receptor subtype and ligand, as proposed by Klaholz et al. 
(2000) the hydrogen bond between an oxygen (most often from a carboxylic 
group) and the arginine R278 was found to be of great importance for the ligand-
protein-interaction.  Figure 1, for example, indicates the carboxylic acid of 
retinoic acid binding to amino acid R278. 
 
 
Figure 1: Retinoic acid binding to human RAR gamma (3LBD), highlighting the distance of 2.1 Å 
between R278 and an oxygen of the carboxylic group of retinoic acid (investigated with PyMOL 
1.3) 
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3.2 Substructures extracted from the ChEMBL database 
 
251 active RAR ligands (pChEMBL ≥ 5) were identified from the ChEMBL 
database and recorded in the supplementary information. Common structural 
features to the ligands, as identified from analysis of the chemical properties and 
visual appearance, were flexibility, a lipophilic scaffold and a terminal hydrogen 
acceptor (e.g. the carbonyl of a carboxylic group).  This information about 
essential molecular substructures and properties was coded in SMARTS strings, 
as shown in Table 1. The first rule is for a carboxylic group, an amide or a ring 
structure derived from these structures, e.g. 1,2,4-oxadiazol-5-one, that has to be 
at the end of a predominately aliphatic chain. Specific aromatic-containing 
scaffolds are possible too (cf. Fig. 3), which are still recognised by the 
substructures from Table 1. Regarding the second rule, the ring structure, e.g. 
cyclohexene in retinoic acid, can be methylated or halogenated, as the ChEMBL 
dataset of active RAR ligands revealed. 
 
Table 1: Structural features of ligands converted to rules for the KNIME workflow 
Rule SMARTS string Structural feature 
1. Arginine (R278) 
binder  
 
*~*~*~*~*~*~*~*~*~*~*~[#6](=O)~[#8]  
 
 
                    or 
 
*~*~*~*~*~*~*~*~*~*~*~[#6](=O)~[#7] 
and 
 
2. Methylated or 
halogenated ring-
system 
*1~*([F,Cl,Br,I,C])~*~*~*~*~1 
“A” or “*” is a wild card, i.e. it could represent any heavy atom 
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Figure 2: Structures of 4-{[(4-Bromo-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-
naphthalenyl)carbonyl]amino}-2,6-difluorobenzoic acid (A) and 4-({5,5-Dimethyl-8-[4-
(trifluoromethyl)phenyl]-5,6-dihydro-2-naphthalenyl}ethynyl)benzoic acid (B) illustrating the 
flexible nature, lipophilic character and terminal hydrogen bonding group of two chemically 
diverse potent RAR ligands 
 
 
 
3.3 Physico-chemical properties 
 
The ranges of the physico-chemical properties calculated for the 251 ChEMBL-
derived RAR ligands are shown in Table 2. The ranges were converted into rules 
which can be used as exclusion critera, i.e. if a compound has a MW of greater or 
equal to 500 Da, then it is, according to the retrieved data, unlikely to be a RAR 
ligand. The rules have some structural basis, i.e. VAIM and MW express the size 
and the complexity of the molecule respectively, and the XLogP describes the 
overall molecular lipophilicity. Beside this basic information the RB indicates the 
required flexibility of the (lipophilic) chain. Generally speaking, the chemical 
space covers small, lipophilic molecules with certain degrees of flexibility within 
the lipophilic scaffold. This is constraint with our understanding of the 
properties of the ligands and their impact on receptor binding. When dealing 
with continuous data, margins of error have been applied to the rules, e.g. lower 
limit for XLogP being 2.00 instead of 2.03 (cf. Table 2). Whilst these are arbitrary, 
they provide a usable buffer. 
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Table 2: Physico-chemical property ranges of the RAR ligands and derived rules 
Descriptor Min Max  Rule 
RB:  4 23  ≥ 4 
VAIM:  5.46 6.40  5 to 6.5 
MW:  278.13 488.25  < 500 
XLogP: 2.03 10.18  ≥ 2.00 
 
 
3.4 Building the KNIME workflow 
 
A KNIME workflow, which can be downloaded from the supplementary 
information, was created combining structural features based on the information 
from PDB and physico-chemical rules based on the ChEMBL dataset. The 
workflow is shown diagrammatically in Figure 3. The workflow takes the 
compound of interest through molecular input, implementation of physico-
chemical and structural rules in turn, resulting in an output of whether the 
compound is in or out of “binding space”. In more detail, the chemical structure 
of interest is imported as a SMILES string. Subsequently physico-chemical 
properties are calculated and the exclusion criteria (cf. Tab. 2) are applied. 
Following this, the structural rules from Table 1 are applied. In this part of the 
workflow, the input SMILES strings, which have already passed the physico-
chemical rules, are run against a set of SMARTS strings, looking for matches 
regarding rule 1, the arginine binder, and rule 2, the methylated/halogenated 
ring-system (cf. Table 1). If a compound’s calculated physico-chemical properties 
is within the defined ranges (cf. Table 2), i.e. it lies within the applicability 
domain, and contains the relevant structural features (cf. Table 1), then the 
compound is classed as having the possibility of being an active RAR ligand. If a 
compound is outside the calculated physico-chemical ranges of Table 2 or does 
not contain the structural features (cf. Table 1), it is classified as being inactive 
towards RAR. Finally the workflow, as it is built in Figure 3, exports a csv-file 
gathering the potential RAR ligands. 
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Figure 3: KNIME workflow to screen for RAR ligands indicating the different  
 
3.5 Evaluating the workflow: Screening two datasets 
 
The workflow was used to screen the active 251 compounds from the ChEMBL 
dataset and all compounds were identified as RAR ligands. 109 of 951 
compounds in the Fourches dataset (Fourches et al., 2010) were identified as 
RAR ligands. Beside retinoids and retinoid-similar structures, some steroids and 
structurally diverse drugs, such as amineptine (tricyclic antidepressant) and 
cocaine (tropane alkaloid) were identified as potential RAR binders. The 
Fourches dataset does not contain information on RAR activity, so performance 
statistics, such as Cooper statistics (Cooper et al., 1979), i.e. false positive ratio, 
sensitivity etc., are not meaningful in this context.  
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4. Discussion  
 
Extrapolation of chemistry to pharmacology or toxicology is a non-trivial, often 
even impossible, task. However, it is recognised that assessing chemicals for 
their pharmacological and toxicological properties is of great importance for 
industry and regulatory agencies. The AOP framework is increasingly seen as 
providing useable information for modelling as it describes the linkage between 
the (bio)chemistry of the MIE and the potential adverse effect on individuals and 
populations (Gutsell and Russell, 2013). A key challenge remains in the 
prediction of chronic toxicity, particularly modes of action relating to organ level 
toxicity. New technologies have the potential to exploit the wealth of data that 
will be delivered from modern database approaches such as ChEMBL and 
increasing reporting of information from molecular biology. To exploit thse data, 
tools and strategies, such as data mining, knowledge extraction techniques and 
(chemo-)informatics tools, are required. Particularly in risk assessment, the 
identification, characterization and application of chemistry from the MIE of an 
AOP is increasingly commonly used method to “group” or form categories of 
similar categories (Vinken et al., 2013; Ankley et al., 2010). Grouping is a crucial 
element of the further use of predictive toxicology approaches, such as read-
across or QSAR and is best undertaken from mechanistic standpoint (Blackburn 
and Stuard, 2014; Patlewicz et al., 2013; Cronin et al., 2013; OECD, 2012). One of 
the key challenges for grouping compounds is the definition of similarity. The 
mechanistic framework provided by the AOP paradigm gives a rational basis to 
developing chemistry based alerts (from the MIE) for grouping and ultimately 
confirming group membership using data from assays representing key event. 
 
This study has applied innovative methods to obtain structural information 
relating to an important MIE. This has been achieved by investigating protein-
ligand binding data. Thus, screening a toxicity dataset with the RAR ligand 
workflow may help to identify compounds acting by the same mechanism and 
therefore belonging in the same group. For such a group of compounds it is more 
likely to develop mechanistically valid, robust QSARs (OECD, 2014; Patlewicz et 
al., 2013; Enoch et al.; OECD 2012; 2011). In drug design, there is an interest in 
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identifying potent RAR agonists to address several types of cancer and skin 
diseases (Alizadeh et al., 2014; Leyden et al., 2005; Allen and Bloxham, 1989; 
Dicken, 1984). The interest may lie in advances towards the receptor-specificity 
(Vaz and de Lera, 2012; Schinke et al., 2010), i.e. significant activity for certain 
receptor subtypes, or pharmacokinetics (el Mansouri et al., 1995), e.g. targeted 
drug localisation. Both strategies may lead to RAR agonists with fewer side 
effects or better risk-benefit ratios. 
 
In this study information from a set of 251 active RAR ligands from ChEMBL and 
20 crystal structures of ligand-protein-interactions from the PDB was extracted 
and investigated to build a screening workflow prediction potential RAR ligands. 
The set of active RAR ligands is based on Ki, Kd, AC50 and EC50 values, that means 
beside agonists, the dataset is also likely to contain antagonists.  However, 
structural and physico-chemical information on antagonists is regarded as 
beneficial to predict agonists, as both share many chemical features. The 
disadvantage of this procedure is a higher likelihood to predict false positives, i.e. 
predicting antagonists as being active. However as a result of the precautionary 
nature of this approach, potential drug candidates in drug discovery and 
potential toxicants should be identified the screening workflow. 
 
As proposed by Klaholz et al. (2000), and confirmed by this study, all ligands are 
small, flexible compounds with lipophilic (mostly aliphatic) scaffolds and a 
(more or less) terminal polar functional group, for example, an amide or a 
carboxylic acid, which creates a hydrogen bond with arginine R278 (PDB, 2014; 
Klaholz et al., 2000). Potent ligands contain at least one ring structure in the 
aliphatic scaffold. Furthermore, ring structures may be halogenated, as this does 
not decrease lipophilicty, such as the compounds illustrated in Figure 2, which 
are highly potent RAR-α binders (Beard et al., 2002; Johnson et al., 1999). 
 
Figure 2 also illustrates the lipophilic (mostly aliphatic) scaffold. As long as 
flexibility and lipophilicity are not greatly impaired, compounds with aromatic 
rings and amides within their scaffold are potential ligands. This explains the 
large number of wild cards within the SMARTS strings (cf. Table 1). These wild 
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cards, which are expressed with a “*”, represent any heavy atom and the wild 
card bond expressed with a “~” represents any type of bond. On its own the 
SMARTS strings developed seem not to be very specific, however due to the rule-
based combination of SMARTS strings and the applicability domains defined by 
physico-chemical attributes, the RAR ligands can be identified with a certain 
degree of specificity. The exact degree of specificity cannot be calculated, but 
when observing the predictions for the Fourches dataset (Fourches et al., 2010), 
where 109 potential RAR ligands out of 951 drug-like compounds were 
predicted, the outcome implies a certain degree of specificity – or better, 
selectivity. According to the analysis of the Fourches, 85 compounds of the 109 
predicted RAR ligands are hepatotoxic. The RAR actives from the ChEMBL 
dataset were all correctly predicted, what indicates high sensitivity. 
 
A screening workflow, as designed as in this study, is assumed to be more 
sensitive than specific, according to the terminology of Cooper et al. (1979), but 
as “conservativeness” is relative. It should be pointed out that KNIME allows for 
the easy adjustment of workflows – without mastering computer language; 
parameters, thresholds and alerts can be changed intuitively. Furthermore it 
shall be pointed out that the purpose of these kind of screening tools is not to 
replace in vitro assays or any other in silico investigation. The main application 
lies in tasks, such as prioritisation, or as a valuable part of an elaborated 
consensus model (cf. integrated testing strategy) and it can also assist in the 
rational grouping of compounds assisting in read-across to predict activity and 
fill data gaps. It is noted that placing this knowledge in the context of the AOP 
framework allows for the grouping and read-across to be supported with 
evidence from assay for other key events (Tollefson et al., 2014).  
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5. Conclusions 
 
A novel approach to build screening tools solely with freeware (at least for 
academia) and open access databases has been described. The flexible design 
within KNIME allows for adjustment and combination of workflows individually 
regarding their purpose and their specific endpoints. Furthermore a prediction 
tool for RAR ligands, as an example for toxicology and pharmacology in equal 
measure, is presented, which may help to identify potential new drugs and 
toxicants.  
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